SystImmune Presents Innovative Data on Iza-bren for Breast Cancer
SystImmune, Inc. has recently announced significant updates in the safety and efficacy profiles of izalontamab brengitecan (iza-bren), which is being investigated as a treatment for locally advanced or metastatic breast cancer. This announcement corresponds with an ongoing Phase 1 clinical study evaluating the promising EGFRxHER3 bispecific antibody-drug conjugate (ADC).
Details of the Presentation
At the upcoming European Society for Medical Oncology (ESMO) Breast 2025 Annual Congress, crucial data from this pivotal study will be showcased. SystImmune is collaborating with Bristol Myers Squibb in the development of iza-bren, reflecting a strong partnership aimed at enhancing cancer treatment options.
Understanding the Clinical Study
The Phase 1 trial primarily focuses on patients diagnosed with locally advanced or metastatic HER2-negative breast cancer. Initial results, which will be presented at ESMO, indicate a robust therapeutic potential even among HER2-negative patients, highlighting the versatility of iza-bren in targeting various breast cancer profiles.
Expert Insights from the Company
Dr. Jonathan Cheng, Chief Medical Officer of SystImmune, expressed optimism regarding the findings, stating, "These data continue to support our conviction that iza-bren demonstrates strong clinical efficacy across a wide variety of tumors such as breast cancer, including those that are HER2 negative, with a manageable safety profile." This perspective underlines SystImmune's commitment to providing effective treatments for patients with limited options.
Key Presentation Information
Here are the details that attendees can look forward to during the ESMO Congress:
- Presentation Title: Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC)
- Presentation No: 302MO
- Session Title: Mini Oral Session 2
- Speaker: Yiqun Du from Shanghai, China
- Session Date & Time: May 16, 2025, from 8:20 AM to 10:10 AM CEST
About Iza-bren and SystImmune
Iza-bren is at the forefront of targeted cancer therapy, designed to effectively bind to EGFR and HER3 proteins, which are frequently expressed in various epithelial tumors. Its innovative mechanism includes blocking these receptors to hinder cancer cell survival signals and inducing cell death through a specialized therapeutic payload.
SystImmune, a dynamic clinical-stage biopharmaceutical company, is pioneering the fight against cancer with its advanced drug development strategies. The company is focusing on expanding its array of bi-specific and antibody-drug conjugate therapies, which exemplify its dedication to innovative cancer treatment. With ongoing clinical trials and a robust pipeline of therapies, SystImmune aims to make significant strides in cancer care.
Frequently Asked Questions
What is izalontamab brengitecan (iza-bren)?
Iza-bren is a bispecific antibody-drug conjugate targeting EGFR and HER3, designed to treat various forms of cancer, including breast cancer.
When will SystImmune present its findings on iza-bren?
SystImmune will present its findings during the ESMO Breast 2025 Annual Congress on May 16, 2025.
How does iza-bren work?
Iza-bren targets specific cancer cell growth factors and blocks their signals, reducing proliferation and activating cell death pathways.
What types of cancer is iza-bren being developed to treat?
This novel therapy aims to address locally advanced or metastatic HER2-negative breast cancer as well as other epithelial tumors.
Who is leading the clinical development of iza-bren?
SystImmune is developing iza-bren in collaboration with Bristol Myers Squibb, focusing on broadening treatment avenues for breast cancer patients.
